Hydrogen's Feasibility and Safety as a Therapy in ECPR
Key facts
- Who runs it
- Boston Children's Hospital
- Where
- Boston, Kansas City, Salt Lake City, and Washington D.C., United StatesSee the 4 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 53 people, planned
- Started
- 4 Mar 2024
- Expected to end
- 31 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hydrogen
- Usual care
- Record updated
- 3 July 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Patients admitted to a cardiac intensive care unit at a participating site with cardiac comorbidity, including congenital heart disease, myocarditis, cardiac arrhythmia, or rejection of a transplanted heart
- Patients are anticipated to be between birth to 18 years of age, although occasionally a patient over the age of 18 may be enrolled
- Patient experiencing a refractory cardiac arrest >5 minutes and receiving ongoing CPR in the ICU, cardiac catheterization lab, or cardiac operating room
- The decision made by the clinical team to resuscitate from ongoing, refractory cardiac arrest using ECPR due to a lack of other available options
Who cannot take part
- Prior ECPR episode during admission (whether or not they were enrolled in the trial)
- Meeting any of the following criterion renders the patient ineligible for the trial:
- Enrollment in the opt-out program
- Patients known to be pregnant
- Patients who are prisoners
- Enrollment does not occur within 6 hours of the decision to resuscitate using ECPR; Note that ECMO cannulation without preceding CPR does not qualify as ECPR and such patients will not be included
This trial is currently available in United States.
- Boston Children's HospitalBoston, United StatesContact: John Kheir, MDTaking people
- Children's Mercy Kansas CityKansas City, United StatesContact: Niranjan Vijayakumar, MBBSNot yet recruiting
- Primary Children's HospitalSalt Lake City, United StatesContact: Stephanie Goldstein, MDNot yet recruiting
- Children's National HospitalWashington D.C., United StatesContact: Bao (Robyn) Nguyen Puente, MDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2% hydrogen in gases administered via the ventilator and ECMO membrane for 72 hours.
The 2 groups in the trial
- Usual care + H2 therapyTreatment being tested
Hydrogen administered via mechanical ventilator and sweep gas into ECMO membrane for 72 hours
Treatment: Hydrogen and Usual care
- Usual careExisting treatment, for comparison
The current standard of care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation
- Publications
- Record updated
- 3 July 2025